Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Defence Therapeutics Inc (DTC.CN)

Defence Therapeutics Inc (DTC.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 61,340
  • Shares Outstanding, K 45,437
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,344 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade DTC.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.19 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2100 +10.74%
on 04/09/24
1.9200 -30.21%
on 03/26/24
-0.3800 (-22.09%)
since 03/19/24
3-Month
1.2100 +10.74%
on 04/09/24
2.3200 -42.24%
on 02/01/24
-0.5300 (-28.34%)
since 01/19/24
52-Week
1.2100 +10.74%
on 04/09/24
3.7400 -64.17%
on 04/20/23
-2.3100 (-63.29%)
since 04/19/23

Most Recent Stories

More News
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth

Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence Therapeutics Announces Warrant Terms Amendment

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developing...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence Completes 2nd Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology

Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update

Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence Therapeutics Completes 1st Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence Financing

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence Begins Trading on the OTCQB and Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)
Defence's AccuTOX(R) Impairs Lung Cancer Growth

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.0500 (+0.96%)
DTC.CN : 1.4500 (+7.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 1.6133
2nd Resistance Point 1.5567
1st Resistance Point 1.4533
Last Price 1.4500
1st Support Level 1.2933
2nd Support Level 1.2367
3rd Support Level 1.1333

See More

52-Week High 3.7400
Fibonacci 61.8% 2.7735
Fibonacci 50% 2.4750
Fibonacci 38.2% 2.1765
Last Price 1.4500
52-Week Low 1.2100

See More

Business Summary

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar